Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:GPR158-MYO16

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: GPR158-MYO16
	FusionPDB ID: 34410
	FusionGDB2.0 ID: 34410
		Hgene	Tgene
	Gene symbol	GPR158	MYO16
	Gene ID	57512	23026
	Gene name	G protein-coupled receptor 158	myosin XVI
	Synonyms	-	MYAP3\|MYR8\|Myo16b\|NYAP3\|PPP1R107
	Cytomap	10p12.1	13q33.3
	Type of gene	protein-coding	protein-coding
	Description	probable G-protein coupled receptor 158	unconventional myosin-XVIMYO16 variant proteinmyosin heavy chain Myr 8neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adapter 3neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 3protein phosphatase 1, regulatory subunit 10
	Modification date	20200313	20200313
	UniProtAcc	Q5T848 Main function of 5'-partner protein: FUNCTION: Orphan receptor.	Q9Y6X6 Main function of 5'-partner protein: FUNCTION: Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Their highly divergent tails are presumed to bind to membranous compartments, which would be moved relative to actin filaments. May be involved in targeting of the catalytic subunit of protein phosphatase 1 during brain development. Activates PI3K and concomitantly recruits the WAVE1 complex to the close vicinity of PI3K and regulates neuronal morphogenesis (By similarity). {ECO:0000250}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000376351, ENST00000490549,	ENST00000467639, ENST00000251041, ENST00000356711, ENST00000357550, ENST00000457511,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	4 X 4 X 3=48	18 X 19 X 10=3420
	# samples	5	21
	** MAII score	log2(5/48*10)=0.0588936890535686 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(21/3420*10)=-4.02553509210714 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: GPR158 [Title/Abstract] AND MYO16 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: GPR158 [Title/Abstract] AND MYO16 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	GPR158(25465251)-MYO16(109644724), # samples:3
Anticipated loss of major functional domain due to fusion event.	GPR158-MYO16 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. GPR158-MYO16 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. GPR158-MYO16 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. GPR158-MYO16 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:25465251/chr13:109644724)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across GPR158 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across MYO16 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000376351	GPR158	chr10	25465251	+	ENST00000356711	MYO16	chr13	109644724	+	5706	1261	359	4534	1391
ENST00000376351	GPR158	chr10	25465251	+	ENST00000251041	MYO16	chr13	109644724	+	2409	1261	359	1780	473
ENST00000376351	GPR158	chr10	25465251	+	ENST00000357550	MYO16	chr13	109644724	+	5692	1261	359	4534	1391
ENST00000376351	GPR158	chr10	25465251	+	ENST00000457511	MYO16	chr13	109644724	+	3084	1261	359	2995	878
ENST00000376351	GPR158	chr10	25465251	+	ENST00000356711	MYO16	chr13	109644723	+	5706	1261	359	4534	1391
ENST00000376351	GPR158	chr10	25465251	+	ENST00000251041	MYO16	chr13	109644723	+	2409	1261	359	1780	473
ENST00000376351	GPR158	chr10	25465251	+	ENST00000357550	MYO16	chr13	109644723	+	5692	1261	359	4534	1391
ENST00000376351	GPR158	chr10	25465251	+	ENST00000457511	MYO16	chr13	109644723	+	3084	1261	359	2995	878

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000376351	ENST00000356711	GPR158	chr10	25465251	+	MYO16	chr13	109644724	+	0.001009047	0.99899095
ENST00000376351	ENST00000251041	GPR158	chr10	25465251	+	MYO16	chr13	109644724	+	0.002036188	0.9979638
ENST00000376351	ENST00000357550	GPR158	chr10	25465251	+	MYO16	chr13	109644724	+	0.001034226	0.99896574
ENST00000376351	ENST00000457511	GPR158	chr10	25465251	+	MYO16	chr13	109644724	+	0.00211822	0.9978817
ENST00000376351	ENST00000356711	GPR158	chr10	25465251	+	MYO16	chr13	109644723	+	0.001009047	0.99899095
ENST00000376351	ENST00000251041	GPR158	chr10	25465251	+	MYO16	chr13	109644723	+	0.002036188	0.9979638
ENST00000376351	ENST00000357550	GPR158	chr10	25465251	+	MYO16	chr13	109644723	+	0.001034226	0.99896574
ENST00000376351	ENST00000457511	GPR158	chr10	25465251	+	MYO16	chr13	109644723	+	0.00211822	0.9978817

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GPR158-MYO16

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
GPR158	chr10	25465251	MYO16	chr13	109644723	1261	299	SAIYGLQPNLVPEFSMQTLDIGILDI
GPR158	chr10	25465251	MYO16	chr13	109644724	1261	299	SAIYGLQPNLVPEFSMQTLDIGILDI

Top

Potential FusionNeoAntigen Information of GPR158-MYO16 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

GPR158-MYO16_25465251_109644723.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:08	QPNLVPEF	0.8701	0.9524	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:01	QPNLVPEF	0.8446	0.9532	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:05	QPNLVPEF	0.8052	0.8026	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B53:01	QPNLVPEF	0.5812	0.7191	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:04	QPNLVPEF	0.4051	0.9802	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:02	QPNLVPEF	0.4051	0.9802	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:01	LQPNLVPEF	0.9988	0.9061	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-A24:20	LQPNLVPEF	0.9748	0.5156	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-A24:15	LQPNLVPEF	0.9722	0.5343	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:03	VPEFSMQTL	0.9721	0.8229	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-A24:25	LQPNLVPEF	0.9719	0.5191	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:01	VPEFSMQTL	0.9692	0.8385	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-A24:31	LQPNLVPEF	0.9689	0.5092	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:25	LQPNLVPEF	0.9578	0.963	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:08	VPEFSMQTL	0.9509	0.7464	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:05	VPEFSMQTL	0.9047	0.5284	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B46:01	LQPNLVPEF	0.9016	0.5645	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:02	VPEFSMQTL	0.8694	0.9149	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:04	VPEFSMQTL	0.8694	0.9149	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:03	LQPNLVPEF	0.8276	0.8877	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-A24:14	LQPNLVPEF	0.7988	0.6957	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B48:01	LQPNLVPEF	0.71	0.5792	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B47:01	LQPNLVPEF	0.5863	0.7036	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B13:01	LQPNLVPEF	0.5146	0.9909	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B52:01	LQPNLVPEF	0.2588	0.9912	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:03	LVPEFSMQTL	0.9185	0.8611	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:02	LVPEFSMQTL	0.8203	0.9466	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:04	LVPEFSMQTL	0.8203	0.9466	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:03	QPNLVPEFSM	0.8183	0.9241	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:04	QPNLVPEFSM	0.5736	0.9831	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:02	QPNLVPEFSM	0.5736	0.9831	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B81:01	QPNLVPEFSM	0.5144	0.7098	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B82:01	QPNLVPEFSM	0.4998	0.6781	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B42:02	QPNLVPEF	0.7454	0.8315	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:12	QPNLVPEF	0.4051	0.9802	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:07	LQPNLVPEF	0.9963	0.7535	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:04	LQPNLVPEF	0.9848	0.9412	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-A24:02	LQPNLVPEF	0.9748	0.5156	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C04:07	VPEFSMQTL	0.9525	0.74	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C04:10	VPEFSMQTL	0.9499	0.7146	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C08:15	VPEFSMQTL	0.9344	0.9382	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:31	LQPNLVPEF	0.9122	0.9374	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:05	LQPNLVPEF	0.9039	0.9329	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:12	VPEFSMQTL	0.8694	0.9149	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B39:10	VPEFSMQTL	0.7198	0.8933	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:19	LQPNLVPEF	0.7192	0.8895	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B39:09	VPEFSMQTL	0.7027	0.5839	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:46	LQPNLVPEF	0.7	0.9575	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:67	LQPNLVPEF	0.6865	0.9769	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:80	LQPNLVPEF	0.6865	0.9769	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:10	LQPNLVPEF	0.6779	0.9855	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:29	LQPNLVPEF	0.6498	0.957	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:13	LQPNLVPEF	0.6104	0.9605	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C04:14	VPEFSMQTL	0.5112	0.7176	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B42:02	VPEFSMQTL	0.4985	0.5492	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B42:01	VPEFSMQTL	0.4377	0.5467	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C01:17	LQPNLVPEF	0.369	0.97	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C01:30	LQPNLVPEF	0.2476	0.9645	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C01:17	LVPEFSMQTL	0.9812	0.9376	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C01:30	LVPEFSMQTL	0.9698	0.9524	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B07:12	QPNLVPEFSM	0.9186	0.557	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-A02:07	LVPEFSMQTL	0.8954	0.6357	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:12	LVPEFSMQTL	0.8203	0.9466	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B56:04	QPNLVPEFSM	0.6858	0.6091	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B42:02	QPNLVPEFSM	0.6101	0.8951	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:12	QPNLVPEFSM	0.5736	0.9831	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B42:01	QPNLVPEFSM	0.5621	0.8898	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B39:10	QPNLVPEFSM	0.3986	0.9705	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:43	QPNLVPEF	0.9313	0.8971	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:11	QPNLVPEF	0.9173	0.9506	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:23	QPNLVPEF	0.856	0.9617	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:77	QPNLVPEF	0.8446	0.9532	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:24	QPNLVPEF	0.8413	0.9472	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:17	QPNLVPEF	0.8208	0.9059	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:30	QPNLVPEF	0.8208	0.9059	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B18:07	QPNLVPEF	0.6895	0.8892	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B53:02	QPNLVPEF	0.6298	0.7283	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:22	QPNLVPEF	0.6036	0.623	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B55:04	QPNLVPEF	0.5584	0.6646	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:09	QPNLVPEF	0.4051	0.9802	6	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:27	LQPNLVPEF	0.9989	0.919	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:33	LQPNLVPEF	0.9988	0.9061	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:125	LQPNLVPEF	0.9988	0.9061	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:34	LQPNLVPEF	0.9988	0.9061	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:135	LQPNLVPEF	0.9986	0.9035	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:50	LQPNLVPEF	0.9984	0.9485	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:24	LQPNLVPEF	0.9972	0.957	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:53	LQPNLVPEF	0.9966	0.8823	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:35	LQPNLVPEF	0.9951	0.8904	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:12	LQPNLVPEF	0.994	0.941	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:23	VPEFSMQTL	0.9714	0.8209	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:77	VPEFSMQTL	0.9692	0.8385	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:54	LQPNLVPEF	0.9671	0.8693	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:13	VPEFSMQTL	0.9638	0.8364	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C04:03	VPEFSMQTL	0.9581	0.7647	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:24	VPEFSMQTL	0.9578	0.8672	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:39	LQPNLVPEF	0.9574	0.9216	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C04:01	VPEFSMQTL	0.9525	0.74	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C08:02	VPEFSMQTL	0.9344	0.9382	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:73	LQPNLVPEF	0.9229	0.9363	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:68	LQPNLVPEF	0.9219	0.6959	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:20	LQPNLVPEF	0.9104	0.9624	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C18:01	VPEFSMQTL	0.9055	0.742	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:20	LQPNLVPEF	0.895	0.9702	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:30	VPEFSMQTL	0.892	0.6978	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:17	VPEFSMQTL	0.892	0.6978	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:28	LQPNLVPEF	0.8906	0.9683	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:13	LQPNLVPEF	0.8883	0.9122	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B15:30	LQPNLVPEF	0.8825	0.9585	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:09	VPEFSMQTL	0.8694	0.9149	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:11	VPEFSMQTL	0.7934	0.8599	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B67:01	VPEFSMQTL	0.7286	0.6655	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B39:11	VPEFSMQTL	0.71	0.6977	10	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:02	LQPNLVPEF	0.6865	0.9769	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B18:04	LQPNLVPEF	0.6005	0.9473	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C07:17	LQPNLVPEF	0.5902	0.9746	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B48:02	LQPNLVPEF	0.5898	0.9621	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B18:08	LQPNLVPEF	0.4211	0.914	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C01:02	LQPNLVPEF	0.3759	0.9695	5	14
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C01:03	LVPEFSMQTL	0.9946	0.9517	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-C01:02	LVPEFSMQTL	0.9827	0.9331	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:09	LVPEFSMQTL	0.8203	0.9466	9	19
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B56:02	QPNLVPEFSM	0.6858	0.6091	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:22	QPNLVPEFSM	0.6645	0.6624	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B55:04	QPNLVPEFSM	0.5861	0.7367	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B35:09	QPNLVPEFSM	0.5736	0.9831	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B82:02	QPNLVPEFSM	0.4998	0.6781	6	16
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	HLA-B67:01	QPNLVPEFSM	0.4141	0.9538	6	16

Top

Potential FusionNeoAntigen Information of GPR158-MYO16 in HLA II

GPR158-MYO16_25465251_109644723.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB1-0102	SAIYGLQPNLVPEFS	0	15
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB1-0123	SAIYGLQPNLVPEFS	0	15
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0101	VPEFSMQTLDIGILD	10	25
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0101	LVPEFSMQTLDIGIL	9	24
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0101	NLVPEFSMQTLDIGI	8	23
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0101	PEFSMQTLDIGILDI	11	26
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0103	VPEFSMQTLDIGILD	10	25
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0103	LVPEFSMQTLDIGIL	9	24
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0103	NLVPEFSMQTLDIGI	8	23
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0103	PEFSMQTLDIGILDI	11	26
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0104	VPEFSMQTLDIGILD	10	25
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0104	LVPEFSMQTLDIGIL	9	24
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0104	NLVPEFSMQTLDIGI	8	23
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0104	PEFSMQTLDIGILDI	11	26
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0106	VPEFSMQTLDIGILD	10	25
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0106	LVPEFSMQTLDIGIL	9	24
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0106	NLVPEFSMQTLDIGI	8	23
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0106	PEFSMQTLDIGILDI	11	26
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0107	VPEFSMQTLDIGILD	10	25
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0107	LVPEFSMQTLDIGIL	9	24
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0107	NLVPEFSMQTLDIGI	8	23
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0107	PEFSMQTLDIGILDI	11	26
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0108	VPEFSMQTLDIGILD	10	25
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0108	LVPEFSMQTLDIGIL	9	24
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0108	NLVPEFSMQTLDIGI	8	23
GPR158-MYO16	chr10	25465251	chr13	109644723	1261	DRB4-0108	PEFSMQTLDIGILDI	11	26

Top

Fusion breakpoint peptide structures of GPR158-MYO16

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7465	QPNLVPEFSMQTLD	GPR158	MYO16	chr10	25465251	chr13	109644723	1261

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GPR158-MYO16

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	7465	QPNLVPEFSMQTLD	-7.9962	-8.1096
HLA-B14:02	3BVN	7465	QPNLVPEFSMQTLD	-5.70842	-6.74372
HLA-B52:01	3W39	7465	QPNLVPEFSMQTLD	-6.83737	-6.95077
HLA-B52:01	3W39	7465	QPNLVPEFSMQTLD	-4.4836	-5.5189
HLA-A11:01	4UQ2	7465	QPNLVPEFSMQTLD	-10.0067	-10.1201
HLA-A11:01	4UQ2	7465	QPNLVPEFSMQTLD	-9.03915	-10.0745
HLA-A24:02	5HGA	7465	QPNLVPEFSMQTLD	-6.56204	-6.67544
HLA-A24:02	5HGA	7465	QPNLVPEFSMQTLD	-5.42271	-6.45801
HLA-B44:05	3DX8	7465	QPNLVPEFSMQTLD	-7.85648	-8.89178
HLA-B44:05	3DX8	7465	QPNLVPEFSMQTLD	-5.3978	-5.5112
HLA-A02:01	6TDR	7465	QPNLVPEFSMQTLD	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of GPR158-MYO16

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
GPR158-MYO16	chr10	25465251	chr13	109644723	10	19	VPEFSMQTL	GGAATTCAGCATGCAGACATTGGATAT
GPR158-MYO16	chr10	25465251	chr13	109644723	5	14	LQPNLVPEF	GCCTAACCTGGTCCCGGAATTCAGCAT
GPR158-MYO16	chr10	25465251	chr13	109644723	6	14	QPNLVPEF	TAACCTGGTCCCGGAATTCAGCAT
GPR158-MYO16	chr10	25465251	chr13	109644723	6	16	QPNLVPEFSM	TAACCTGGTCCCGGAATTCAGCATGCAGAC
GPR158-MYO16	chr10	25465251	chr13	109644723	9	19	LVPEFSMQTL	CCCGGAATTCAGCATGCAGACATTGGATAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
GPR158-MYO16	chr10	25465251	chr13	109644723	0	15	SAIYGLQPNLVPEFS	CATCTACGGGTTGCAGCCTAACCTGGTCCCGGAATTCAGCATGCA
GPR158-MYO16	chr10	25465251	chr13	109644723	10	25	VPEFSMQTLDIGILD	GGAATTCAGCATGCAGACATTGGATATTGGAATATTGGACATTTT
GPR158-MYO16	chr10	25465251	chr13	109644723	11	26	PEFSMQTLDIGILDI	ATTCAGCATGCAGACATTGGATATTGGAATATTGGACATTTTTGG
GPR158-MYO16	chr10	25465251	chr13	109644723	8	23	NLVPEFSMQTLDIGI	GGTCCCGGAATTCAGCATGCAGACATTGGATATTGGAATATTGGA
GPR158-MYO16	chr10	25465251	chr13	109644723	9	24	LVPEFSMQTLDIGIL	CCCGGAATTCAGCATGCAGACATTGGATATTGGAATATTGGACAT

Top

Information of the samples that have these potential fusion neoantigens of GPR158-MYO16

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	GPR158-MYO16	chr10	25465251	ENST00000376351	chr13	109644723	ENST00000251041	TCGA-C8-A1HO

Top

Potential target of CAR-T therapy development for GPR158-MYO16

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to GPR158-MYO16

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to GPR158-MYO16

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)